폴리필 제품 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2024-2029년)

The Polypill Products Market size is estimated at USD 32.80 billion in 2024, and is expected to reach USD 36.20 billion by 2029, growing at a CAGR of 2% during the forecast period (2024-2029).

COVID-19 had an indirect impact on the polypill products market. The strict lockdowns and government regulations intended to slow the spread of COVID-19 resulted in decreased product demand across product segments. The COVID-19 virus primarily affected the lungs, causing severe acute respiratory distress syndrome. It was later observed that it also affected other organs, including the heart. Cardiovascular complications associated with COVID-19 were comprehensive and included cardiac injury, arrhythmia, and heart failure. A study by the National Health Commission of China 2021 reported that some patients presented primarily cardiovascular symptoms, such as palpitations and chest tightness, rather than respiratory symptoms during the initial occurrence of COVID-19. The secondary impact of COVID-19 on patient's cardiovascular systems increased the demand for its treatment; however, the demand for the polypill increased during the pandemic. According to guidelines issued by the Medical Associations during the pandemic in 2021, cardiac treatments for COVID-19-affected patients included standard heart failure therapies, steroid-based drugs, anticoagulation treatments, aspirin to prevent microclots, and, if required, cardiac surgery. Thus, the demand for the polypill during the COVID-19 pandemic remained unpredictable due to the lack of research studies on the use of a polypill on COVID-19-diagnosed patients with cardiovascular disorders.

The polypill is a pill that has a combination of several drugs commonly used to treat heart disease and high blood pressure. The polypill is a safe, effective, and usable strategy to improve compliance in people at risk of cardiovascular disease (CVD). Some of the significant advantages of polypill that are expected to boost the adoption of polypill products during the forecast period include the cost-effective pill, combination of multiple drugs in one dosage form, high adherence among the elderly population, and a rise in utilization of polypill products. One of the major advantages of polypill products over other formulations is lower dosages of different medications, which, in turn, are projected to reduce the side effects. The key players apply several marketing strategies to increase their market presence and share. For instance, key players are planning to promote polypill products as easy-to-remember medicament and convenient as the USP to improve company sales. Moreover, polypill has also emerged as a low-cost medication alternative and is likely to replace therapies that require multiple medications. In August 2023, the WHO contained three fixed-dose combinations of polypills on its revised Model Lists of Essential Medicines (EML) 2023 for primary and secondary precluding atherosclerotic cardiovascular diseases.

The rising prevalence of CVD globally is driving the polypill market growth rate as polypill is proven to be an effective medication for CVD treatment. For instance, in December 2022, the American Heart Association, Inc. published that 244.1 million people lived with ischemic heart disease (IHD) globally, and the global prevalence of heart stroke in 2020 was 89.1 million people, whereas that of ischemic stroke was 68.2 million, that of intracerebral hemorrhage was 18.9 million, and that of subarachnoid hemorrhage was 8.1 million.

Polypill is a fixed-dose combination used in the treatment of various chronic diseases. This combination of pharmacotherapy can decrease the incidence and prevalence of cardiovascular and other diseases. The cost of product and treatment is a significant factor influencing treatment selection. Therefore, the low cost of polypill products is boosting adoption.

The ramification of polypill ingestion in patients is expected to hamper the market growth during the forecast period. The medication dosages are difficult to adjust in a polypill prescription; due to this, the side effects observed in the patients are cough, muscle aches, and stomach irritation.

Polypill Products Market Trends

The multi-parameter polypill Segment is Expected to Witness Significant Growth Over the Forecast Period

The multi-parameter polypill has played a significant role in developing the polypill market growth rate over the years. The multi-parameter polypill is projected to hold a significant market share during the forecast period. The factors responsible for the multi-parameter polypill segment's rapid growth are rising demand for the multi-parameter polypill over the single parameter polypill, multi-parameter polypill preferred by physicians over the standard individual medications, and multi-parameter polypill availability on all distribution channels.

Several key players are investing and developing multi-parameter polypills for multiple disease parameters. For instance, CardioPharma is developing a multi-parameter polypill CardiaPill (CP-101), with Aspirin, simvastatin, and lisinopril composition to target several cardiac factors. Also, Tehran University is developing Poly Pill 4-2 with a combination of Aspirin, enalapril/valsartan, atorvastatin, and hydrochlorothiazide to treat the multi-parameters of cardiac disease.

By definition, a polypill is a fixed-dose combination of medicines with proven benefits for the detection of CVD. The multi-parameter polypill or cardiovascular polypill is a type of polypill that comprises several pharmaceutical components, each lowering one of the significant cardiovascular risk factors that has around 3 to 4 components and is targeted at 3 to 4 risk factors. The multi-parameter polypill is directed to cardiovascular patients who are moderate to high-risk. The multi-parameter polypill is utilized to improve overall cardiovascular risk control in the population, improve adherence, and reduce side effects. The cost of this polypill is relatively less than the single parameter polypill. Hence, the multi-parameter polypill segment is expected to hold a significant share during the forecast period.

The increasing demand for multi-parameter polypill is due to the rapid rise in cardiovascular diseases in developing regions where the medical infrastructure is improving steadily. Also, 3D printing technology is used to develop the multi-parameter polypill to enhance product performance in personalized medicine areas. For instance, in July 2023, the International Journal of Pharmaceutics published a paper that stated that Fused deposition modeling (FDM) 3D printing technology coupled with hot-melt extrusion (HME) had been successfully applied in the manufacture of polypills containing nifedipine (NFD), as an antihypertensive drug, simvastatin (SMV), as an antihyperlipidemic drug, and gliclazide (GLZ) as an anti glycemic drug.

Therefore, the multi-parameter Polypill segment is projected to expand significantly during the forecast period due to the abovementioned factors.

North America is Expected to Dominate the Polypill Products Market

North America is anticipated to dominate the market due to factors such as high awareness among healthcare practitioners about new medicines in the region, an increase in sedentary lifestyle in the United States, new product launches, high healthcare expenditure & disposable income, and the presence of key companies in the region are among the key factors contributing to the growth of the studied market in North America.

The rising prevalence of hypertension is expected to drive the growth of the polypill products market in North America, as the demand for these drugs, specifically for hypertension, is remarkably high. For instance, according to the Centers for Disease Control and Prevention, 2023, heart disease costs the United States about USD 239.9 billion each year; this includes the cost of health care services, medicines, and lost productivity due to death. The high rate of hospitalization and high cost of cardiovascular treatment in the United States makes the country a significant market share holder during the forecast period.

Therefore, owing to the aforementioned factors, the growth of the polypill market is anticipated in North America.

Polypill Products Industry Overview

The polypill products market is consolidated, as only a few players currently dominate the global market. The competitive landscape includes an analysis of a few international as well as local companies that hold the market shares and are well known, including Amra Remedies, AstraZeneca, Cadila Pharmaceuticals, Cipla, Inc., Dr Reddy's Laboratories, East West Pharma, Excella Life Sciences Pvt. Ltd., Grupo Ferrer Internacional, S.A., Janssen Global Services, LLC, Merck & Co., Pfizer, Inc., and Takeda Pharmaceutical Company Limited among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence and Incidence of Cardiovascular Diseases
  • 4.2.2 Growing Research and Development Activities
• 4.3 Market Restraints
  • 4.3.1 Ramification of Polypill Ingestion in Patient
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Type
  • 5.1.1 Single Parameter Polypill
  • 5.1.2 Multi-parameter Polypill
• 5.2 By Application
  • 5.2.1 Cardiovascular
  • 5.2.2 Diabetes Mellitus
  • 5.2.3 Others
• 5.3 By Distribution Channel
  • 5.3.1 Online Pharmacies
  • 5.3.2 Hospital Pharmacies
  • 5.3.3 Retail Pharmacies
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Amra Remedies
  • 6.1.2 AstraZeneca
  • 6.1.3 Cadila Pharmaceuticals
  • 6.1.4 Cipla, Inc.
  • 6.1.5 Dr Reddy-s Laboratories
  • 6.1.6 East West Pharma
  • 6.1.7 Excella Life Sciences Pvt. Ltd.
  • 6.1.8 Grupo Ferrer Internacional, S.A.
  • 6.1.9 Janssen Global Services, LLC
  • 6.1.10 Merck & Co
  • 6.1.11 Pfizer, Inc.
  • 6.1.12 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS